Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

[Angiotensin-2 type 1 receptors (AT1R) and cancers].

Dolley-Hitze T, Verhoest G, Jouan F, Le Pogamp P, Arlot-Bonnemains Y, Oger E, Belaud-Rotureau MA, Rioux-Leclercq N, Vigneau C.

Nephrol Ther. 2013 Apr;9(2):85-91. doi: 10.1016/j.nephro.2012.09.006. Review. French.

PMID:
23332110
3.

Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study.

van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH.

Cancer. 2008 Feb 15;112(4):748-57. doi: 10.1002/cncr.23215.

4.

[Angiotensin II receptor blockers: current status and future prospects].

Corvol P, Plouin PF.

Drugs. 2002;62 Spec No 1:53-64. Review. French.

PMID:
12036389
5.
6.
7.

Angiotensin inhibition and malignancies: a review.

Rosenthal T, Gavras I.

J Hum Hypertens. 2009 Oct;23(10):623-35. doi: 10.1038/jhh.2009.21. Review.

PMID:
19339998
8.

Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.

Böger CA, Götz AK, Krüger B, Hösl M, Schmitz G, Riegger GA, Krämer BK.

Eur J Med Res. 2005 Apr 20;10(4):161-8.

PMID:
15946912
9.

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME.

J Hypertens. 2005 Mar;23(3):463-73. Review.

PMID:
15716683
10.

Rationale for combining blockers of the renin-angiotensin system.

Azizi M, Wuerzner G.

Semin Nephrol. 2007 Sep;27(5):544-54. Review.

PMID:
17868792
11.

Role of the renin-angiotensin system in gynecologic cancers.

Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, Mabuchi Y, Yagi S, Minami S, Tanizaki Y, Kobayashi A, Kikkawa F.

Curr Cancer Drug Targets. 2011 May;11(4):405-11. Review.

PMID:
21395551
12.

Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy.

Molteni A, Heffelfinger S, Moulder JE, Uhal B, Castellani WJ.

Anticancer Agents Med Chem. 2006 Sep;6(5):451-60. Review.

PMID:
17017854
13.

Novel drugs targeting hypertension: renin inhibitors.

Danser AH.

J Cardiovasc Pharmacol. 2007 Aug;50(2):105-11. Review.

PMID:
17703126
14.

On target to dual block RAS?

Papadopoulos DP, Papademetriou V, Makris TK.

Angiology. 2009 Dec-2010 Jan;60(6):739-49. doi: 10.1177/0003319708329799. Review.

PMID:
19144653
15.

Manipulating the angiotensin system--new approaches to the treatment of solid tumours.

Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S, Kikkawa F.

Expert Opin Biol Ther. 2006 Mar;6(3):243-55. Review.

PMID:
16503734
16.

Pharmacologic modulation of ACE2 expression.

Soler MJ, Barrios C, Oliva R, Batlle D.

Curr Hypertens Rep. 2008 Oct;10(5):410-4. Review.

PMID:
18775121
17.

Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists.

Izzo JL Jr, Moser M.

J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6 Suppl 2):11-9, 31. Review.

19.
20.

Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition.

Sullivan JC.

Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1220-6. doi: 10.1152/ajpregu.00864.2007. Review.

Items per page

Supplemental Content

Support Center